Quarterly ResultAug 6, 2026, 07:25 AM
Ironwood Raises 2026 Guidance; Q2 Revenue $113M, Net Income $51M
AI Summary
Ironwood Pharmaceuticals reported strong second quarter 2026 results, with total revenue reaching $113 million and GAAP net income of $51 million. Building on this performance, the company raised its full-year 2026 financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA. Additionally, Ironwood repaid $200 million in convertible notes and initiated the confirmatory Phase 3 STARS-2 trial for apraglutide, its lead pipeline asset.
Key Highlights
- Raised full-year 2026 LINZESS U.S. net sales guidance to $1.15 - $1.20 billion.
- Raised full-year 2026 total revenue guidance to $460 - $485 million.
- Raised full-year 2026 adjusted EBITDA guidance to greater than $310 million.
- Q2 2026 LINZESS U.S. net sales were $282 million, up 14% year-over-year.
- Q2 2026 total revenue was $113 million, compared to $85.2 million in Q2 2025.
- Q2 2026 GAAP net income was $51 million, or $0.31 per share.
- Repaid $200 million convertible notes using cash on hand.
- Initiated STARS-2 confirmatory Phase 3 trial for apraglutide in SBS-IF.
Price Impact
More from IRWD